Lonza Group AG Stock
Price
Target price
€615.00
€615.00
0.070%
0.4
0.070%
-
19:24 / Tradegate
WKN: 928619 / Symbol: LZAGF / Name: Lonza Group / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Lonza Group
sharewise wants to provide you with the best news and tools for Lonza Group, so we directly link to the best financial data sources.
Financials
News
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations
Lonza Appoints Hans Trees as Global Head of Communications
Lonza Appoints Hans Trees as Global Head of Communications
Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Delivers Strong Performance in Q1 2026 in Line with Expectations and Confirms Full-Year Outlook 2026
Lonza Delivers Strong Performance in Q1 2026 in Line with Expectations and Confirms Full-Year Outlook 2026
Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports
Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports
Lonza Nominates Stephen Fry as Independent Board Member
Lonza Nominates Stephen Fry as Independent Board Member
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients
Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients